Saniona AB (SANION):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Saniona AB (SANION) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8257
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Saniona AB (Saniona), formerly Aniona is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company’s pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which is used to treat obesity and type 2 diabetes; tesomet, a fix-dosed combination of tesofensine and metoprolol for the treatment of type 2 diabetes and prader-willi syndrome; and NS2359, a triple monoamine reuptake inhibitor, which is used to treat cocaine addiction. It also develops CAD-1883, a program for treatment of ataxia and essential tremors. The company conducts research on three classes of ion channels including GABAA receptors, nicotinic acetylcholine receptors and potassium channels. Saniona is headquartered in Ballerup, Denmark.

Saniona AB (SANION) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Saniona AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Saniona AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Saniona AB, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 11
Saniona Acquires Assets from NeuroSearch 12
Saniona Acquires Technical Platforms from NeuroSearch 13
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 14
Partnerships 15
Boehringer Ingelheim Enters into Research Agreement with Saniona 15
Saniona Enters into Agreement with Productos Medix 16
Saniona Enters into Agreement with Syngene 17
Saniona Extends R&D Agreement with Ataxion 18
Equity Offering 19
Initiator Pharma to Raise USD2.4 Million in Rights Offering of Units 19
Scandion Oncology Raises USD0.3 Million in Private Placement of Shares 20
Saniona Raises USD4 Million in Private Placement of Shares 21
Scandion Oncology Spins-Off from Saniona 22
Initiator Pharma Raises USD2.3 Million in Rights Offering of Shares 23
Initiator Pharma Spins Out from Saniona 24
Saniona Completes IPO For US$2.6 Million 25
Debt Offering 26
Saniona to Raise USD8.7 Million in Private Placement of Bonds 26
Asset Transactions 27
Ataxion Acquires Ataxia Program from Saniona 27
Saniona AB – Key Competitors 28
Saniona AB – Key Employees 29
Saniona AB – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 22, 2018: Saniona publishes its interim report for the second quarter 2018 31
May 24, 2018: Saniona publishes its interim report for the first quarter 2018 32
Feb 21, 2018: Saniona publishes its year-end report for 2017 33
Nov 15, 2017: Saniona publishes its interim report for the third quarter 2017 34
Aug 23, 2017: Saniona publishes its interim report for the second quarter 2017 35
Feb 21, 2017: Saniona publishes year-end report for 2016 36
Corporate Communications 37
Dec 22, 2017: Saniona: The Nomination Committee of Saniona Proposes Election of Two Additional Members of the Board of Directors 37
May 31, 2017: Saniona approved for listing on Nasdaq Stockholm’s main market 39
Product News 40
10/03/2017: Saniona obtains Research Milestone from The Michael J. Fox Foundation for Parkinsons Research of about USD 119,487 40
04/20/2017: Saniona: Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson’s Research 41
Clinical Trials 42
Dec 04, 2017: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching 42
Sep 18, 2017: Saniona reports encouraging start for tesofensine Phase 3 study 43
Aug 21, 2017: Saniona’s Partner, Medix, Initiates Phase 3 Study for tesofensine in Obesity 44
Apr 12, 2017: Saniona’s partner, Medix, obtains approval to initiate Phase 3 study in obesity 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Saniona AB, Pharmaceuticals & Healthcare, Key Facts 2
Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Saniona AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Saniona AB, Deals By Therapy Area, 2012 to YTD 2018 9
Saniona AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 11
Saniona Acquires Assets from NeuroSearch 12
Saniona Acquires Technical Platforms from NeuroSearch 13
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 14
Boehringer Ingelheim Enters into Research Agreement with Saniona 15
Saniona Enters into Agreement with Productos Medix 16
Saniona Enters into Agreement with Syngene 17
Saniona Extends R&D Agreement with Ataxion 18
Initiator Pharma to Raise USD2.4 Million in Rights Offering of Units 19
Scandion Oncology Raises USD0.3 Million in Private Placement of Shares 20
Saniona Raises USD4 Million in Private Placement of Shares 21
Scandion Oncology Spins-Off from Saniona 22
Initiator Pharma Raises USD2.3 Million in Rights Offering of Shares 23
Initiator Pharma Spins Out from Saniona 24
Saniona Completes IPO For US$2.6 Million 25
Saniona to Raise USD8.7 Million in Private Placement of Bonds 26
Ataxion Acquires Ataxia Program from Saniona 27
Saniona AB, Key Competitors 28
Saniona AB, Key Employees 29
Saniona AB, Subsidiaries 30

List of Figures
Saniona AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Saniona AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Saniona AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Saniona AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Saniona AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Saniona AB (SANION):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT. Indonesia Power:企業の戦略的SWOT分析
    PT. Indonesia Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Bancolombia SA (BCOLOMBIA):企業の財務・戦略的SWOT分析
    Bancolombia SA (BCOLOMBIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Chembio Diagnostic, Inc. (CEMI)-医療機器分野:企業M&A・提携分析
    Summary Chembio Diagnostic, Inc. (Chembio) develops, manufactures, markets and licenses point-of-care diagnostic (POCs) tests for the detection of infectious diseases. The company offers products to prevent the spread of infectious diseases with solutions like Dual Path Platform (DPP), which makes P …
  • Huntington Ingalls Industries Inc:戦略・SWOT・企業財務分析
    Huntington Ingalls Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Huntington Ingalls Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Bone Therapeutics SA (BOTHE):企業の財務・戦略的SWOT分析
    Summary Bone Therapeutics SA (Bone Therapeutics) is a cell therapy company that develops autologous and allogeneic cell therapy products. It offers pipeline products such as PREOB, an autologous osteoblastic cell therapy product used for the treatment of osteonecrosis and non-union fractures; and AL …
  • Exxaro Resources Ltd:企業の戦略・SWOT・財務分析
    Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tokyo Electric Power Company Holdings Incorporated (9501)-石油・ガス分野:企業M&A・提携分析
    Summary Tokyo Electric Power Company Holdings, Incorporated (TEPCO), formerly Tokyo Electric Power Company, Incorporated, is an integrated energy company. The company generates, transmits, distributes and sells electricity through its subsidiaries. It generates power from various sources such as the …
  • Alarko Contracting Group
    Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report Summary Alarko Contracting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Kinpo Electronics Inc (2312):企業の財務・戦略的SWOT分析
    Kinpo Electronics Inc (2312) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Prosafe SE (PRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Prosafe SE (Prosafe) is a provider of semi-submersible accommodation support and service vessels to the oil and gas industry. The company’s operations are related to maintenance and modification of installations on fields already in production, hook-up and commissioning of new fields, tie-ba …
  • AMTEC Corporation:企業の戦略・SWOT・財務情報
    AMTEC Corporation - Strategy, SWOT and Corporate Finance Report Summary AMTEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • The Gap, Inc.:企業の戦略・SWOT・財務情報
    The Gap, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Gap, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BP Plc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    BP Plc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary BP Plc (BP) is an integrated oil and gas company. Its upstream activities include exploration, development and production of oil and natural gas, field development and production; and midstream operations inc …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Promigas SA ESP (PROMIGAS):企業の財務・戦略的SWOT分析
    Promigas SA ESP (PROMIGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Triple-S Management Corp (GTS):企業の財務・戦略的SWOT分析
    Triple-S Management Corp (GTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Gabather AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Gabather AB (Gabather) is a developer of new drug candidates for the treatment of central nervous system diseases. The company spans its expertise in the development of anti-psychotics, anti-depressants and anxiolytics, analgesics, and cognition-enhancing treatments. It offers drug candidate …
  • Scripps Health:企業の戦略的SWOT分析
    Scripps Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Phagelux Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Phagelux Inc (Phagelux) is an anti-infectives company that provides antibacterial products and solutions. The company uses phage lysis enzymes and biological agents for the treatment of antibiotic resistant bacteria and related diseases in human beings and crops. Its product portfolio includ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆